MedCity News
DECEMBER 26, 2023
AstraZeneca is paying $1 billion up front to acquire Gracell Biotechnologies, a clinical-stage cell therapy developer. The deal is the latest in a series of AstraZeneca moves intended to expand its presence in the burgeoning cell therapy field.
Evolve Your Success
DECEMBER 26, 2023
There is a myth that medical sales are very hard to get into, but if you put the time and effort into this program, you will get the job that you want. This is what Joseph “Joey” Hutchison learned from his successful journey in medical sales. After going through the Medical Sales Career Builder program, he was able to break into trauma med sales in just three months.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
DECEMBER 26, 2023
By acquiring RayzeBio, Bristol Myers Squibb gains a pipeline of radiopharmaceuticals and the infrastructure for manufacturing these targeted cancer therapies. In the second half of 2023 alone, BMS has committed about $24 billion to business development deals.
pharmaphorum
DECEMBER 26, 2023
AstraZeneca agrees a $1.
Advertiser: ZoomInfo
AI adoption is reshaping sales and marketing. But is it delivering real results? We surveyed 1,000+ GTM professionals to find out. The data is clear: AI users report 47% higher productivity and an average of 12 hours saved per week. But leaders say mainstream AI tools still fall short on accuracy and business impact. Download the full report today to see how AI is being used — and where go-to-market professionals think there are gaps and opportunities.
MedCity News
DECEMBER 26, 2023
In looking ahead to 2024, the healthcare industry stands at the cusp of a transformative era of transparency. With impending regulatory changes and growing consumer empowerment, the landscape is poised for continued meaningful progress.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
DECEMBER 26, 2023
The contributors to food insecurity include age, having a disability, being on a fixed income and being a single parent, according to a recent report from FarmboxRx.
Pharmaceutical Technology
DECEMBER 26, 2023
Bristol Myers Squibb (BMS) has signed a definitive agreement for the acquisition of Karuna Therapeutics for $14bn in cash.
MedCity News
DECEMBER 26, 2023
Hospitals and hospital systems need to make clearer and more consistent demands for climate accountability from their suppliers, and they need to follow through with preferred green vendor programs and the like.
PharmExec
DECEMBER 26, 2023
As this exciting technology exploded in 2023, Pharm Exec was there to cover it all.
Speaker: Jesse Hunter and Brynn Chadwick
Today’s buyers expect more than generic outreach–they want relevant, personalized interactions that address their specific needs. For sales teams managing hundreds or thousands of prospects, however, delivering this level of personalization without automation is nearly impossible. The key is integrating AI in a way that enhances customer engagement rather than making it feel robotic.
Pharmaceutical Technology
DECEMBER 26, 2023
KSQ-4279 is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Ovarian Cancer.
PharmExec
DECEMBER 26, 2023
Five trends in pharmaceutical marketing from the past year.
Spotio
DECEMBER 26, 2023
Manufacturing sales is anything but simple. Fortunately, it’s far from impossible. You just need to implement an effective manufacturing sales strategy to meet your company’s revenue goals. We can help you with that! Once you equip your sales team with the strategy and technology they need to close deals, they’ll do so at a consistent clip.
Pharmaceutical Technology
DECEMBER 26, 2023
In 2023, investors pursued pharmaceutical assets with value amidst an unstable economic environment.
Advertiser: ZoomInfo
ZoomInfo customers aren’t just selling — they’re winning. Revenue teams using our Go-To-Market Intelligence platform grew pipeline by 32%, increased deal sizes by 40%, and booked 55% more meetings. Download this report to see what 11,000+ customers say about our Go-To-Market Intelligence platform and how it impacts their bottom line. The data speaks for itself!
Rep-Lite
DECEMBER 26, 2023
Recruiting medical staff, including non-clinical roles such as device equipment specialists, department managers, or medical sales representatives, involves several complexities due to the unique nature of the healthcare industry. Medical sales staff recruitment firms may face challenges such as finding the right talent, ensuring compliance, incorporating innovation, and others.
Pharmaceutical Technology
DECEMBER 26, 2023
AWT-020 is under clinical development by Anwita Biosciences and currently in Phase II for Sarcomas.
PharmaTech
DECEMBER 26, 2023
WHO provides a look at the world’s health as the agency turns 75.
Pharmaceutical Technology
DECEMBER 26, 2023
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).
Speaker: Kevin Burke
AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. This webinar will provide a practical introduction to AI, focusing on its current applications, transformative potential, and strategies for successful implementation in your organization. Using real-world examples and actionable insights, we’ll examine how businesses are leveraging AI to increase efficiency, enhance personalization, and drive measurable results.
Pharmaceutical Commerce
DECEMBER 26, 2023
Items in this sector ranged touched on topics such as pharma shipping, container technology, and sustainability.
Pharmaceutical Technology
DECEMBER 26, 2023
Exarafenib is under clinical development by Kinnate Biopharma and currently in Phase I for Non-Small Cell Lung Cancer.
Pharmacy Times
DECEMBER 26, 2023
From newsworthy moments to groundbreaking research, these were the most-read cardiovascular-related articles on Pharmacy Times in 2023.
Pharmaceutical Technology
DECEMBER 26, 2023
AZD-9550 is under clinical development by AstraZeneca and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Advertiser: ZoomInfo
Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.
Pharmacy Times
DECEMBER 26, 2023
From newsworthy moments to groundbreaking research, these were the most-read Clostridioides difficile-related articles on Pharmacy Times in 2023.
Pharmaceutical Technology
DECEMBER 26, 2023
ADRX-0706 is under clinical development by Adcentrx Therapeutics and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).
Pharmacy Times
DECEMBER 26, 2023
From newsworthy moments to groundbreaking research, these were the most-read heart failure-related articles on Pharmacy Times in 2023.
Pharmaceutical Technology
DECEMBER 26, 2023
GS-4528 is under clinical development by Gilead Sciences and currently in Phase I for Metastatic Renal Cell Carcinoma.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
MedCity News
DECEMBER 26, 2023
Ambreen Molitor, Planned Parenthood’s national director of venture and innovation, discussed three partnerships her organization has launched this year to address barriers to abortion care. These partnerships tackle barriers such as cost, changing state laws and lack of emotional support.
Pharmaceutical Technology
DECEMBER 26, 2023
BGB-30813 is under clinical development by BeiGene and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).
Pharmaceutical Technology
DECEMBER 26, 2023
ORB-011 is under clinical development by Orionis Biosciences and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).
Expert insights. Personalized for you.
314 
Let's personalize your content